Trials / Completed
CompletedNCT01488162
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
Non Interventional Study Aimed to Describe the Management of Relapse or Refractory Chronic Lymphocytic Leukemia (CLL) Patients Retreated by MabThera
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 327 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multi-center, prospective, observational study will describe the management of relapsing or refractory chronic lymphocytic leukemia (CLL) patients. Data will be collected for 2 years.
Conditions
Timeline
- Start date
- 2011-04-04
- Primary completion
- 2016-10-24
- Completion
- 2016-10-24
- First posted
- 2011-12-08
- Last updated
- 2017-03-22
Locations
84 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01488162. Inclusion in this directory is not an endorsement.